Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity

v3.19.3
Stockholders' Equity
9 Months Ended
Sep. 30, 2019
Stockholders' Equity  
Stockholders' Equity

Note 5 — Stockholders’ Equity

Stock Purchase Transaction

On February 8, 2019, InvaGen acquired 5,833,333 shares of the Company’s common stock at $6.00 per share for net proceeds of $31.5 million after deducting commission fees and other offering costs, representing a 33.3% stake in the Company’s capital stock on a fully diluted basis.

Equity Incentive Plan

The Company has in effect the 2015 Incentive Plan (“2015 Incentive Plan”). The 2015 Incentive Plan was adopted in December 2015 by our stockholders. Under the 2015 Incentive Plan, the compensation committee of the Company’s board of directors is authorized to grant stock-based awards to directors, officers, employees and consultants. The plan authorizes grants to issue up to 2,000,000 shares of authorized but unissued common stock and expires 10 years from adoption and limits the term of each option to no more than 10 years from the date of grant.

Restricted Stock Units and Restricted Stock Awards

The following table summarizes restricted stock unit and award activity for the nine months ended September 30, 2019:

 

 

 

 

 

 

 

 

 

 

 

Weighted

 

 

Number of Units

 

Average Grant

 

    

and Awards

    

Date Fair Value

Unvested balance at December 31, 2018

 

1,104,643

 

$

4.45

Granted

 

261,173

 

$

5.95

Vested

 

(250,654)

 

$

4.41

Unvested balance at September 30, 2019

 

1,115,162

 

$

4.86

 

 

For the three months ended September 30, 2019 and 2018, stock-based compensation expenses associated with the amortization of restricted stock units and restricted stock awards for employees and non-employees were approximately $0.3 million and $0.4 million, respectively. For the nine months ended September 30, 2019 and 2018, stock-based compensation expenses associated with the amortization of restricted stock units and restricted stock awards for employees and non-employees were approximately $1.6 million and $1.0 million, respectively.

At September 30, 2019, the Company had unrecognized stock-based compensation expense related to restricted stock units and restricted stock awards of $1.4 million, which is expected to be recognized over the remaining weighted-average vesting period of 1.5 years.  This amount does not include, as of September 30, 2019, 361,173 shares of restricted stock outstanding which are performance-based and vest upon achievement of certain corporate milestones. The expense is recognized over the vesting period of the award. Stock-based compensation for milestone awards will be measured and recorded if and when it is probable that the milestone will be achieved.

Stock Options

The following table summarizes stock option award activity for the nine months ended September 30, 2019:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average

 

 

 

 

Weighted

 

Remaining

 

 

 

 

Average Exercise

 

Contractual Life

 

    

Stock Options

    

Price

    

(in years)

Outstanding, December 31, 2018

 

20,000

 

$

6.29

 

3.63

Cancelled/forfeited

 

(20,000)

 

 

6.29

 

 —

Outstanding, September 30, 2019

 

 —

 

$

 —

 

 —

 

 

Stock Warrants

The following table summarizes the warrant activity for the nine months ended September 30, 2019:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted

 

Aggregate

 

 

 

 

Average Exercise

 

Intrinsic Value

 

    

Warrants

    

Price

    

(in thousands)

Outstanding, December 31, 2018

 

102,597

 

$

0.0976

 

$

544

Exercised

 

(85,308)

 

$

0.0001

 

 

 —

Outstanding, September 30, 2019

 

17,289

 

$

0.5786

 

$

93